NMR-based metabolomics studies of human prostate cancer tissue

• Type: Another Publication in an International Scientific Journal
• Date: 2018

Authors

Lima, AR (Author) Other; Pinto, J (Author) Other; Maria de Lourdes Bastos (Author) FFUP; Carvalho, M (Author) Other; de Pinho, PG (Author) FFUP

Journal

Title: Metabolomics

Vol. 14

ISSN: 1573-3882

Publisher: Springer Nature

Indexing

ISI Web of Knowledge - 19 Citations

Scopus - 19 Citations

Other information

Authenticus ID: P-00R-A7X

DOI: 10.1007/s11306-018-1384-2

Abstract (EN): Prostate cancer (PCa) is one of the most prevalent cancers in men worldwide. Serum prostate-specific antigen (PSA) remains the most used biomarker in the detection and management of patients with PCa, in spite of the problems related with its low specificity, false positive rate and overdiagnosis. Furthermore, PSA is unable to discriminate indolent from aggressive PCa, which can lead to overtreatment. Early diagnosed and treated PCa can have a good prognosis and is potentially curable. Therefore, the discovery of new biomarkers able to detect clinically significant aggressive PCa is urgently needed. This revision was based on an electronic literature search, using Pubmed, with Nuclear Magnetic Resonance (NMR), tissue and prostate cancer as keywords. All metabolomic studies performed in PCa tissues by NMR spectroscopy, from 2007 until March 2018, were included in this review. In the context of cancer, metabolomics allows the analysis of the entire metabolic profile of cancer cells. Several metabolic alterations occur in cancer cells to sustain their abnormal rates of proliferation. NMR proved to be a suitable methodology for the evaluation of these metabolic alterations in PCa tissues, allowing to unveil alterations in citrate, spermine, choline, choline-related compounds, lactate, alanine and glutamate. The study of the metabolic alterations associated with PCa progression, accomplished by the analysis of PCa tissue by NMR, offers a promising approach for elucidating biochemical pathways affected by PCa and also for discovering new clinical biomarkers. The main metabolomic alterations associated with PCa development and promising biomarker metabolites for diagnosis of PCa were outlined.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 11